Edgewise Therapeutics Sees Unusually Large Options Volume (NASDAQ:EWTX)

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) saw unusually large options trading activity on Thursday. Stock investors acquired 3,952 put options on the stock. This is an increase of approximately 400% compared to the average daily volume of 790 put options.

Edgewise Therapeutics Stock Up 54.4 %

Edgewise Therapeutics stock traded up $10.38 during midday trading on Thursday, reaching $29.45. The stock had a trading volume of 7,211,353 shares, compared to its average volume of 912,651. Edgewise Therapeutics has a 52-week low of $5.12 and a 52-week high of $29.57. The company has a fifty day moving average of $18.73 and a 200 day moving average of $17.96. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -16.12 and a beta of 0.15.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. Equities research analysts predict that Edgewise Therapeutics will post -1.48 EPS for the current year.

Institutional Trading of Edgewise Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new stake in Edgewise Therapeutics in the 1st quarter valued at about $162,502,000. Novo Holdings A S purchased a new stake in Edgewise Therapeutics in the second quarter worth about $114,263,000. Baker BROS. Advisors LP raised its holdings in shares of Edgewise Therapeutics by 87.6% in the 1st quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock valued at $106,523,000 after purchasing an additional 2,727,273 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Edgewise Therapeutics by 89.0% during the first quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock valued at $73,278,000 after purchasing an additional 1,892,053 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. raised its stake in Edgewise Therapeutics by 12.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,731,067 shares of the company’s stock worth $67,197,000 after buying an additional 427,500 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Piper Sandler restated an “overweight” rating and issued a $48.00 price objective on shares of Edgewise Therapeutics in a research report on Monday, July 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $32.00 price target on shares of Edgewise Therapeutics in a report on Tuesday. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Edgewise Therapeutics in a research note on Friday, August 16th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, August 12th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $33.40.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.